ALXO · CIK 0001810182 · operating
ALX Oncology is a clinical-stage biopharmaceutical company developing immuno-oncology therapies for cancer treatment. The company's primary focus is Evorpacept, a CD47-blocking therapeutic that works by modulating the immune system to enhance anti-cancer responses. Evorpacept is being evaluated in multiple Phase 1 and Phase 2 clinical trials as a combination therapy with established cancer drugs across several indications, including gastric cancer, urothelial cancer, and head and neck squamous cell carcinoma.
The company has established multiple collaboration agreements with pharmaceutical manufacturers and academic institutions to expand the development pipeline. Partners include Jazz Pharmaceuticals, Sanofi, MD Anderson Cancer Center, and the University of Pittsburgh, among others. Additionally, ALX maintains a license agreement for the development of ALTA-002, a myeloid-targeting immune activator being co-developed with Tallac Therapeutics.
As a clinical-stage company, ALX Oncology has not generated meaningful product revenues. The organization operates with 44 full-time employees and is based in South San Francisco, California. The company is incorporated in Delaware and trades on the Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.58 | $-2.58 | +31.0% | |
| 2023 | $-3.74 | $-3.74 | -23.4% | |
| 2022 | $-3.03 | $-3.03 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |